Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.
Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma. 
Introduction
Although malignant melanoma comprises only 4% of all dermatologic cancers, it accounts for more than 75% of deaths from skin cancer. Surgical resection remains the only effective cure for tumors that have not yet reached a depth of greater than 1 mm. However, prognosis rapidly declines with more advanced stages and the current 5- year survival averages at approximately 15% for metastatic melanoma [1, 2] . Furthermore, melanoma is one of the most common causes of cancer deaths between 20 and 35 years of age [3] , resulting in an immense socioeconomic impact. Thus, research is needed to define newer therapeutic targets, as current treatment options for advanced malignant melanoma have failed to show satisfactory results [1] [2] [3] .
The stages of progression of normal melanocytes to malignant melanoma can be divided into: (i) benign nevus; (ii) dysplastic nevus; (iii) radial growth phase; (iv) vertical growth phase; and (v) metastatic melanoma [4] . These histological changes can be related to alterations of specific key genes [5, 6] . Chromosomal deletions, mutations and amplifications play a major role in these transformations. However, recent investigations have revealed that epigenetic events may be equally important in carcinogenesis.
DNA methylation is involved in epigenetic silencing of genes
The term 'epigenetics' refers to heritable changes in gene expression, which are not caused by changes in the DNA nucleotide sequence, but rather result from modification in the DNA backbone and DNA packaging [7] [8] [9] . The best-studied epigenetic event so far is DNA methylation. DNA methylation occurs by covalent addition of a methyl group at the 5 0 carbon of the cytosine ring, resulting in 5-methylcytosine. This process is catalyzed by DNA methyltransferases (DNMTs) and takes place only at cytosine bases located 5 0 to a guanosine base in a CpG dinucleotide [7, 8] . These CpGs can be clustered in small stretches of DNA termed 'CpG islands' [10] . Approximately 70% of human gene promoters are associated with a CpG island [11] . Promoter CpG islands are normally unmethylated in euchromatin (the part of the genome, that is actively transcribed and translated), but show a heavy methylation pattern in heterochromatin (part of genome where activity and expression are suppressed) to facilitate transcriptional silencing of noncoding regions [12] (Fig. 1) . Examples of such fully methylated CpG islands associated with silent genes can be found on the inactive X chromosome in females and in silenced alleles of some imprinted genes (genes that are expressed only from either maternal or paternal allele) [10] . However, aberrant promoter methylation of genes that control cell cycle and apoptosis can lead to disruption of normal cell division and can contribute to carcinogenesis.
Although most of the work in melanoma has focused on gene-silencing events caused by hypermethylation, it is important to mention that cytosine methylation can influence tumorigenicity by other mechanisms. It has been shown, for example, that histone deacetylation -another epigenetic event leading to transcriptional silencing -can be stimulated by cellular machinery triggered by aberrant methylation [13] [14] [15] [16] . There is also growing evidence that hypermethylation can actually predispose to mutational events as it has been shown in MLH1 and O6methylguanine DNA methyltransferase (MGMT) -two DNA repair genes where aberrant methylation resulted in microsatellite instability increasing the frequency of mutations [17] [18] [19] . 5-methylcytosine itself has been shown to be mutagenic and can potentially undergo spontaneous hydrolytic deamination causing C-T transitions [20] . In addition, with regard to malignant melanoma it is important to mention that the presence of methyl groups in CpG dinucloutides in coding regions of TP53 increases the rate of mutations induced by ultraviolet light by shifting the ultraviolet absorption spectrum for cytosine to a region in spectrum that is prevalent in sunlight [21] .
DNA methyltransferases and their inhibitors
As explained above, DNMTs catalyze the covalent addition of methyl groups to cytosine residues in DNA. The most common functional DNMTs in mammalian cells include DNMT1, DNMT3a and DNMT3b [22, 23] . The most abundant one -DNMT1 -seems to be responsible for maintaining established patterns of DNA methylation, whereas DNMT3a and DNMT3b seem to play a role in the establishment of new, de-novo, methylation [24, 25] . It has been shown, however, that DNMT1 in cancer cells was not solely responsible for maintaining abnormal methylation patterns suggesting that DNMT3s may cooperate for this function in malignancies [26, 27] . Although DNMT1 and DNMT3b were earlier known to promote tumor growth and play important roles in cancer cell survival and tumorigenesis [25, 28] , the role of DNMT3a in carcinogenesis remains mostly unknown. A recent study by Deng et al. [28] now suggests that DNMT3a also has a significant impact on tumor growth and metastasis formation in malignant melanoma. Several DNMT inhibitors have been used in experimental and clinical trials, the most common one being 5-aza-2 0 -deoxycytidine, also known as DAC or decitabine. As a cytidine analog, decitabine, is incorporated into newly synthesized DNA where it covalently links with DNMTs, which potentially induces cell death and cell damage by obstructing DNA synthesis and structural instability at the site of incorporation [29] [30] [31] . DNMTs are depleted by being bound to these agents and are thereby unavailable for methylation, resulting in significant demethylation after repeated replication [25, 32] . DNMT inhibitors are inactivated by deamination by cytidine deaminase [33] .
Methylated genes in melanoma
Abnormal patterns of DNA methylation in melanoma have been recognized over the last few years and so far more than 70 aberrantly hypermethylated genes have been discovered (Tables 1 and 2 ). These genes have been found to be hypermethylated either by direct examination of the methylated CpGs (Table 1) or indirectly by their activation upon treatment with demethylating agents ( Table 2 ). Most of this work has been carried out in melanoma cell lines. Interestingly, cell lines of malignant tumors, in general, seem to have a higher level of CpG island hypermethylation than their primaries. Paz et al. [58] who investigated 70 different cell lines from 12 different tumors -including malignant melanoma -compared the methylation status of the cultured cell lines to their primary tumors. Cultured cell lines showed 5 0 CpG hypermethylation in 26.6 versus 17% in primary tumors. The studies reflected in this article seem to have an equal tendency towards increased promoter hypermethylation in cultured cell lines. Table 1 contains 34 studies where aberrant methylation was tested in melanoma cell lines as well as in melanoma tumor samples. Twenty-five of the 34 studies showed increased methylation in melanoma cell lines compared with their primary tumors, whereas two studies showed equal methylation patterns and seven showed increased methylation in the primary tumors as compared with the cell lines. Despite these limitations, some genes have been consistently shown to be hypermethylated in melanoma and its cell lines and have even been implicated in the progression of mole to malignant melanoma. The role of these genes in the pathobiology of melanoma is now reviewed in greater detail. p16 (INK4A) is a tumor suppressor gene found on chromosome 9p21 and is one of the two genes encoded by CDKN2A (cyclin-dependent kinase inhibitor 2A) -the Mechanism of aberrant methylation. Transcription starts at the promoter site and is only able to proceed when no aberrant methylation is found as seen in (a). (b) Multiple methylated CpGs in the promoter region. The methyl groups project into major grooves of DNA and effectively inhibit transcription and gene expression. , unmethylated; , methylated. Koga et al. [11] Normal skin n = 7 and nevi n = 2 0/9 (0%) Early-stage melanomas n = 8 3/8 (38%) Advanced-stage melanomas n = 16 9/16 (56%) Freedberg et al. [48] 1/9 (11%) in 192 other one being p14 (ARF). A total of 25-40% of familial melanomas have genetic alterations within the CDKN2A gene [61] and the majority of sporadic melanomas also exhibit a large amount of genetic/epigenetic events within this locus [62, 63] . INK4A blocks the cell cycle at the G1-S checkpoint by inhibiting cyclin-D-dependent kinases, CDK4 and CKD6, thereby activating the tumorsuppressive effects of the retinoblastoma protein [5, 6] . Mice lacking INK4A are abnormally prone to the development of tumors; however, development of melanoma in such mice requires additional epigenetic events in other regulatory genes [64, 65] .
p14 (ARF) derives its name from the use of an alternative reading frame of the exons it shares with p16INK4A. p14ARF plays a crucial role in maintaining p53 levels by controlling ubiquitination of the p53 protein. It acts through binding to and thereby neutralizing MDM2 (mouse double minute 2) protein, which triggers ubiquitination of p53 eventually leading to its destruction in the proteosome [66,67] (Fig. 2) . Stress signals are transmitted to p14ARF in part through DAPK, a deathassociated protein kinase. Activation of p14ARF eventually leads to increased p53 activity and cell apoptosis. Epigenetic silencing of p14 can thus lead to loss of p53mediated apoptosis and tumor development. Interestingly, p53 itself has not shown to be grossly altered in malignant melanoma [56, 68] . However, recent investigations have discovered another gene -Apaf1 (apoptotic protease activating factor 1, Chromosome 12q22) -that acts with cytochrome c and caspase 9 to mediate p53 dependent apoptosis [69] . Activation of p53 leads to stimulation and release of cytochrome c in the mitochondria thereby activating Apaf1, which in turn stimulates caspase 9 eventually leading to cell death [68] . Furthermore, it has been shown that there exists a strong inverse correlation between Apaf1 expression and melanoma progression [70, 71] . Soengas et al. [56] showed that treatment of Apaf1 negative Melanoma cell lines with 5-Aza-dC lead to re-expression of Apaf 1 and reduction of cell growth. Paradoxically, a 5-CpG hypermethylation could not be found within the promoter region of the (SK MEL-5, SK MEL-19,  SK MEL-28, SK MEL-29, SK MEL-85, SK MEL-94,  SK MEL-100, SK MEL-103, SK MEL-147,  SK MEL-173, SK MEL-197, Malme-3M, UACC-62 Gallaghar et al. Apaf1 gene indicating possibly a different mechanism of Apaf1 silencing, which could be reversed with demethylating agents.
Phosphatase and tensin homologue (PTEN) is a tumor suppressor gene that is located on chromosome 10q23. It encodes a phosphatase that inhibits signaling by a variety of growth factors that use phosphatidylinositolphosphatate (PIP3) as an intracellular signal. PIP3 becomes activated through the phosphatidylinositol-3-kinase and in turn triggers stimulation of AKT (also known as protein kinase B). Activated AKT inactivates proteins that suppress the cell cycle or stimulate apoptosis, thereby increasing proliferation and survival of cells. Mouse models have shown that suppression of AKT leads to reduced survival and growth of melanoma cells [72] ; the amount of active AKT increases progressively during melanoma tumor progression with highest levels present in advanced-stage metastatic melanomas [73] . PTEN antagonizes phosphatidylinositol-3-kinase activity by deactivating PIP3, thereby reducing AKT levels [5, 6] . Epigenetic inactivation of PTEN can thus result in activation of the AKT pathway and lead to tumor development.
RASSF1A is a recently identified tumor suppressor gene, which has been studied with increasing interest since its first description in 2000 [74] . It is located in the 3p21.3 region of the human genome and has been found to be hypermethylated in various cancers [75] [76] [77] [78] . Considering that RASSF1A also suffers point mutations in up to 15% of cancers, it is one of the most frequently inactivated proteins identified in neoplasms [79] . RASSF1a is a Ras effector that interacts with Ras GTPases promoting various cellular events including apoptosis, migration and mitosis [79, 80] (Fig. 3) . Mice whose RASSF1A gene has been knocked out exhibit increased tendency to develop spontaneous tumors [81, 82] . Re-expression of the RASSF1A gene in nude mice reduces tumorgenecity [80] . RASSF1A has been found to hypermethylated in up to 80% of samples in some studies. Interestingly, the degree of methylation seems to increase with progressing tumor stage. Tanemura et al. [42] showed that RASSF1A was not methylated in stage I and II melanoma, however, aberrant methylation was present in almost 50% of stage IV melanoma, indicating that RASSF1A might play a role as a marker of progression and prognosis in malignant melanoma.
Retinoic acid receptor b-2 (RAR-b2) silencing has been recently implicated in carcinogenesis as there is convincing evidence that it acts as putative tumor suppressor genes; however, its exact mechanism in tumor suppression needs yet to be defined. Loss of RAR-b2 expression has been shown to be progressive in various premalignant and malignant tissues and increased expression correlates with clinical response [42, 83, 84] . Houle et al. [85] showed that lung carcinoma cells expressing transfected RAR-b2 are less tumorigenic in nude mice and transgenic mice expressing antisense RAR-b2 develop lung cancer [86] . The precise molecular mechanisms responsible for RAR-b2 mediated antitumor activity are not fully understood, but possibly include suppressed expression of EGFR, activating protein-1 and COX-2 and the phosphorylation of extracellular signal-regulated protein kinases 1 and 2 [83, 87] . In malignant melanoma, the frequency of aberrant methylation and loss of expression of this protein are as high as 70% [40] . Bostick et al. [88] showed a significant correlation between hypermethylation of RAR-b2 and increasing primary tumor Breslow thickness. Interestingly, however, the frequency of aberrant methylation seems to be similar in primary as well as in metastatic tumor [40, 42] suggesting that RAR-b2 might play a role in initiation and progression of primary malignant melanoma, but not in metastasis formation.
Other genes, which have been shown to be hypermethylated in malignant melanoma, but whose role in tumorigenesis needs yet to be defined are suppressor of cytokine signaling (SOCS), MGMT, and TNFRSF10 receptors. SOCS proteins have emerged as key physiological regulators of cytokine-mediated Jak-Stat signaling; including responses to interferon, suggesting a role in the suppression of carcinogenesis [89] . MGMT is a DNA repair protein involved in the reversal of DNA alkylation. Mitochondria DNA methylation and its effects on the apoptosis pathways. Promoter methylation causes silencing of DAPK and p14 ARF decreasing thereby the inhibitory effect of p14ARF on MDM2 which in turn leads to increased ubiquitination and degradation of p53. p53 itself has not shown to be aberrantly methylated; however, DNA methylation can predispose to gene mutations altering thereby functions of p53. Apaf 1, a newly recognized proapoptotic factor, has been shown to be underexpressed in cancer cells. Treatment with decitabine can restore Apaf1 function, interestingly, however, the Apaf1 promoter was not found to be hypermethylated suggesting a different mechanism of gene silencing, which can be reversed with demethylating agents. Apaf1 activates in conjunction with caspase 9 (Ca) and caspase 3 (Ca 3) leading ultimately to cell death.
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Reduced MGMT expression as well as enzyme activity may result in an increased susceptibility to DNA alkylation and carcinogenesis [46] . TNF-related apoptosisinducing ligand, also known as TNFRSF10, is a protein that belongs to the tumor necrosis factor (TNF) ligand family and preferentially induces apoptosis in transformed and tumor cells. TNF-related apoptosis-inducing ligand or TNFSF10 binds to at least five receptors including R1 (DR4), R3 (DcR1), and R4 (DcR2). It is thought that underexpression of these receptors leads to reduced TRIAL/TNFSF10-mediated apoptosis.
Hypomethylation and gene activation in malignant melanoma
Despite the increased prevalence of aberrant promotor hypermethylation in cancer, it has been shown paradoxically that tumor cells are globally hypomethylated when compared with wild-type cells [90, 91] . There are suggestions that hypomethylation can contribute to carcinogenesis through the activation of oncogenes and triggering of chromosome instability, as methylation of pericentromeric regions contributes to chromosome stability [10] . In malignant melanoma, hypomethylation has been shown to lead to activation of a number of Cancer testis (CT) genes, of which some examples include melanoma antigen genes (MAGE), BAGE (B melanoma antigen), GAGE, and NY-ESO-1 [92] [93] [94] . CT genes code for protein antigens with normal expression in adult testicular germ cells that can also be aberrantly activated and expressed in a range of human cancers. As CT antigens are tumor specific and are not expressed in somatic tissue, they have elicited increasing interest as a target for immunotherapy and vaccines [95, 96] . Although the biological function of CT genes in both the germ line and tumors remains poorly understood, it has been shown that the higher frequency of CT expression in tumors is often correlated with worse outcome and that CT antigens might play a role in tumorigenesis [95, 97] . Clinical trials to evaluate MAGE-A3 and NY-ESO-1 as therapeutic cancer vaccine targets in malignant melanoma patients have been conducted and have shown some promising results in inhibiting melanoma progression [98, 99] . A common feature of CT antigen gene expression is the induction by DNMT inhibitors such as decitabine, emphasizing hypomethylation as an important factor in activating CT gene expression [95] . Interestingly, when treating both, normal tissue and cancer cell lines with decitabine, Karpf et al. [92] showed that MAGE-A1 was hypomethylated in normal as well as in cancer cell lines; however, the gene was expressed only in the cancer line suggesting that other transcriptional activators are required to express hypomethylated genes. Further investigation is needed to define the role and mechanism of hypomethylation in cancer and to determine the impact of CT antigens in tumorigenesis and as target for immunotherapy.
Translational implications of aberrant DNA methylation in melanoma
Methylation patterns could serve as diagnostic and prognostic biomarkers and be used in screening and risk assessment of cancer patients.
Use of aberrant DNA methylation marks in diagnosis and prognosis
De-novo methylation of CpG islands occurs early in carcinogenesis and it has been shown that these epigenetic changes can be detected in sputum, serum, and urine samples [10] . Presumably, cancer cells release their DNA into the circulation after apoptosis or necrosis, after which it can be detected by simple blood tests. In malignant melanoma patients, Mirmohammadsadegh et al. [52] detected aberrant methylated PTEN DNA in 62% of peripheral blood specimens. Marini et al. [89] were able to extract aberrant methylated SOCS 1 and 2, CDKN2a, RASSF1a and MGMT from peripheral sera of patients with malignant melanoma. Paz et al. [58] analyzed different tumor cell lines and found that cell lines of a defined histological originincluding leukemia, melanoma, glioma, head and neck, thyroid, and lymphoma cell lines -could be grouped according to their specific hypermethylation profiles by clustering these cell lines into independent terminal branches specific to their respective organ types. These findings might lead to the development of molecular strategies for cancer detection and as a marker of recurrence after tumor excision. Furthermore, there is strong evidence that DNA methylation of selected genes increases quantitatively and qualitatively with tumor stages, implying that CpG island methylator phenotypes predict progression of melanoma suggesting worse prognosis with increasing degrees of methylation [42] . Although these findings seem promising Multiple effects of RASSF1A. Its functions as a tumor suppressor gene have shown to be secondary to cell cycle arrest in the G 1 and G 1 /S phase through interaction with cyclin D1 and A2 and mitotic arrest by interacting with the microtubule function. It is also thought that RASSF1A might play a role in the apoptosis pathway.
in using aberrant methylation as a parameter of diagnosis and prognosis more research is warranted to further determine the sensitivity and specificity of such testing.
Using methylation marks in treatment and response to therapy
The current mainstay of therapy in advanced melanoma consists of chemotherapeutic agents in conjunction with immune modulators such as interferon or interleukin-2, an approach also called biochemotherapy. Patient response to such treatment is, however, difficult to predict and tumor-specific markers indicating the degree of response would be of tremendous clinical value [39] .
Mori et al. [39] investigated methylation patterns in responders of biochemotherapy to nonresponders and showed that the frequency of circulating RASSF1A methylated DNA was significantly lower in responders than in nonresponders. The results imply that an increased degree of methylation does not only correlate with the worse prognosis but also correlates with the resistance to therapy. Consequently, the use of demethylating agents has been implied in various clinical settings to improve outcome in cancer patients with aberrant methylation patterns [59, 100] . For example, decitabine is active in a variety of liquid cancers including myelodysplastic syndrome and acute myeloid leukemia [34, 52, [101] [102] [103] [104] ; however, clinical trials for solid tumors, such as melanoma, have yielded rather disappointing results when decitabine was used as a single agent [105] [106] [107] [108] [109] . These findings are currently being re-evaluated using decitabine for potentiation of immune response or resensitization to chemotherapy. There is clinical evidence that decitabine in combination with IL-2 might enhance activity of IL-2 in melanoma [110] or overcome resistance to interferon-induced apoptosis [111] , thus improving patient outcomes.
Conclusion and perspective
The discovery of epigenetic changes in carcinogenesis over the last few decades has opened the door to new strategies in treatment, diagnosis, and prognosis in cancer. Unlike mutagenic events, epigenetic changes can be reversed and potentially restore the function of key control genes and pathways in premalignant and malignant cells. However, the complexity of epigenetic events and interactions between epigenetic and mutagenic changes is not yet fully understood. Aberrant promoter methylation and loss of gene expression is found in an increasing number of genes, but for most of these genes it remains to be determined to what extent their loss of function contributes to tumorigenesis or whether their promoter methylation is just a natural process of aging. Furthermore, there is a possibility that cells might have their own DNA-demethylating activities to protect themselves from aberrant methylation. Agius et al. [112] were able to show that the plant Arabidopsis thaliana possesses an enzyme (glycosylase/lyase), which actively demethylates DNA and it seems quite possible that human cells also might have enzymes with demethylating capacity. When used in clinical settings, demethylating agents act nonspecifically on methylated DNA and can potentially reexpress genes, that are intended to be silenced like protooncogenes, or can lead to hypomethylation which in turn causes chromosomal instability. Although such events have yet not been reported in clinical trials, there are studies showing that targeting DNMT-1 in mice is associated with an increased incidence of lymphoma [113, 114] . Future investigation will certainly aim to precisely evaluate the molecular effects of demethylating agents in cancerous and normal tissue.
